Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors

Hypoxia, a deficiency in the levels of oxygen, is common feature most solid tumors and induces many characteristics cancer. Hypoxia associated with metastases strong resistance to radio- chemotherapy, can decrease accuracy cancer prognosis. Non-invasive imaging methods such as positron emission tomography (PET) single-photon computed (SPECT) using hypoxia-targeting radiopharmaceuticals have been used for detection therapy tumor hypoxia. Nitroimidazoles are bioreducible moieties that be selectively reduced under hypoxic conditions covalently bind intracellular macromolecules, trapped within cells tissues. Recently, there has motivation develop PET SPECT radiotracers containing nitroimidazole visualization treatment tumors. In this review, we summarize development some novel nitroimidazoles, well their physicochemical properties, vitro cellular uptake values, vivo biodistribution, PET/SPECT results.